-
1
-
-
64949096235
-
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation
-
Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12(36).
-
(2008)
Health Technol Assess
, vol.12
, Issue.36
-
-
Wang, D.1
Cummins, C.2
Bayliss, S.3
Sandercock, J.4
Burls, A.5
-
2
-
-
12944252177
-
Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: A population-based retrospective study
-
Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatrics 2004;4(25):1-7.
-
(2004)
BMC Pediatrics
, vol.4
, Issue.25
, pp. 1-7
-
-
Fjaerli, H.O.1
Farstad, T.2
Bratlid, D.3
-
3
-
-
0842349460
-
Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease
-
Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004;23:S41-S45.
-
(2004)
Pediatr Infect Dis J
, vol.23
-
-
Cabalka, A.K.1
-
4
-
-
25844453682
-
-
British Medical Association and Royal Pharmaceutical Society of Great Britain, No. 59. London: BMA and RPS
-
British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. London: BMA and RPS; 2010.
-
(2010)
British national formulary
-
-
-
5
-
-
4544286541
-
-
Anon, London: National Institute for Health and Clinical Excellence
-
Anon. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2009.
-
(2009)
Guide to the methods of technology appraisal
-
-
-
6
-
-
33644888074
-
Hospitalization for respiratory syncytial virus infection in young children: Development of a clinical prediction rule
-
Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MW, de Groot R, Moll HA, et al. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J 2006;25(3):201-7.
-
(2006)
Pediatr Infect Dis J
, vol.25
, Issue.3
, pp. 201-207
-
-
Rietveld, E.1
Vergouwe, Y.2
Steyerberg, E.W.3
Huysman, M.W.4
de Groot, R.5
Moll, H.A.6
-
7
-
-
4944259712
-
Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease
-
Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89(10):961-5.
-
(2004)
Arch Dis Child
, vol.89
, Issue.10
, pp. 961-965
-
-
Duppenthaler, A.1
Ammann, R.A.2
Gorgievski-Hrisoho, M.3
Pfammatter, J.P.4
Aebi, C.5
-
8
-
-
34748906209
-
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease
-
Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7(9):1471-80.
-
(2007)
Expert Opin Biol Ther
, vol.7
, Issue.9
, pp. 1471-1480
-
-
Feltes, T.F.1
Sondheimer, H.M.2
-
9
-
-
70349406752
-
Risk factors for RSV hospitalisation in children with heart disease
-
Kristensen K, Stensballe LG, Bjerre JV, Roth D, Fisker N, Kongstad T, et al. Risk factors for RSV hospitalisation in children with heart disease. Arch Dis Child 2009;94(10):785-9.
-
(2009)
Arch Dis Child
, vol.94
, Issue.10
, pp. 785-789
-
-
Kristensen, K.1
Stensballe, L.G.2
Bjerre, J.V.3
Roth, D.4
Fisker, N.5
Kongstad, T.6
-
10
-
-
17944391919
-
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group
-
Simoes EA, Sondheimer HM, Top FH, Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133(4):492-9.
-
(1998)
J Pediatr
, vol.133
, Issue.4
, pp. 492-499
-
-
Simoes, E.A.1
Sondheimer, H.M.2
Top Jr., F.H.3
Meissner, H.C.4
Welliver, R.C.5
Kramer, A.A.6
-
11
-
-
0033940772
-
Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study. IRIS Study Group
-
Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19(7):592-7.
-
(2000)
Pediatr Infect Dis J
, vol.19
, Issue.7
, pp. 592-597
-
-
Carbonell-Estrany, X.1
Quero, J.2
Bustos, G.3
Cotero, A.4
Domenech, E.5
Figueras-Aloy, J.6
-
12
-
-
0242298724
-
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
-
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-40.
-
(2003)
J Pediatr
, vol.143
, Issue.4
, pp. 532-540
-
-
Feltes, T.F.1
Cabalka, A.K.2
Meissner, H.C.3
Piazza, F.M.4
Carlin, D.A.5
Top Jr., F.H.6
-
13
-
-
0031683919
-
Palivisumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants
-
The IMpact-RSV Study Group
-
The IMpact-RSV Study Group. Palivisumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7.
-
(1998)
Pediatrics
, vol.102
, Issue.3
, pp. 531-537
-
-
-
14
-
-
0034821962
-
Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons
-
IRIS Study Group
-
Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20(9):874-9.
-
(2001)
Pediatr Infect Dis J
, vol.20
, Issue.9
, pp. 874-879
-
-
Carbonell-Estrany, X.1
Quero, J.2
-
15
-
-
0036269392
-
Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting
-
Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002;91(5):593-8.
-
(2002)
Acta Paediatr
, vol.91
, Issue.5
, pp. 593-598
-
-
Eriksson, M.1
Bennet, R.2
Rotzen-Ostlund, M.3
von Sydow, M.4
Wirgart, B.Z.5
-
16
-
-
6344280211
-
Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain
-
IRIS Study Group
-
Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23(9):815-20.
-
(2004)
Pediatr Infect Dis J
, vol.23
, Issue.9
, pp. 815-820
-
-
Figueras-Aloy, J.1
Carbonell-Estrany, X.2
Quero, J.3
-
17
-
-
58849101190
-
A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study
-
Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78.
-
(2008)
Respir Res
, vol.9
, pp. 78
-
-
Simoes, E.A.1
Carbonell-Estrany, X.2
Fullarton, J.R.3
Liese, J.G.4
Figueras-Aloy, J.5
Doering, G.6
-
18
-
-
53049109274
-
FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks
-
Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, Fernandez-Colomer B, Guzman-Cabanas J, Echaniz-Urcelay I, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27(9):788-93.
-
(2008)
Pediatr Infect Dis J
, vol.27
, Issue.9
, pp. 788-793
-
-
Figueras-Aloy, J.1
Carbonell-Estrany, X.2
Quero-Jimenez, J.3
Fernandez-Colomer, B.4
Guzman-Cabanas, J.5
Echaniz-Urcelay, I.6
-
19
-
-
47149094332
-
Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry
-
Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008;28(7):511-17.
-
(2008)
J Perinatol
, vol.28
, Issue.7
, pp. 511-517
-
-
Frogel, M.1
Nerwen, C.2
Cohen, A.3
van Veldhuisen, P.4
Harrington, M.5
Boron, M.6
-
20
-
-
52249108047
-
Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand
-
Grimwood K, Cohet C, Rich FJ, Cheng S, Wood C, Redshaw N, et al. Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect 2008;136(10):1333-41.
-
(2008)
Epidemiol Infect
, vol.136
, Issue.10
, pp. 1333-1341
-
-
Grimwood, K.1
Cohet, C.2
Rich, F.J.3
Cheng, S.4
Wood, C.5
Redshaw, N.6
-
21
-
-
6344278290
-
The Pediatric Investigators Collaborative Network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation
-
Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23(9):806-14.
-
(2004)
Pediatr Infect Dis J
, vol.23
, Issue.9
, pp. 806-814
-
-
Law, B.J.1
Langley, J.M.2
Allen, U.3
Paes, B.4
Lee, D.S.5
Mitchell, I.6
-
22
-
-
44049087819
-
Comment on the Austrian consensus paper on prophylaxis of RSV infection with palivizumab and post-RSV respiratory tract disease
-
Liese J. Comment on the Austrian consensus paper on prophylaxis of RSV infection with palivizumab and post-RSV respiratory tract disease. Monatsschrift fur Kinderheilkunde 2008;156(4):384.
-
(2008)
Monatsschrift fur Kinderheilkunde
, vol.156
, Issue.4
, pp. 384
-
-
Liese, J.1
-
23
-
-
10744231314
-
Respiratory syncytial virus infection--risk factors for hospital admission: A case-control study
-
Nielsen HE, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst CH, Norgaard-Pedersen B, et al. Respiratory syncytial virus infection--risk factors for hospital admission: a case-control study. Acta Paediatr 2003;92(11):1314-21.
-
(2003)
Acta Paediatr
, vol.92
, Issue.11
, pp. 1314-1321
-
-
Nielsen, H.E.1
Siersma, V.2
Andersen, S.3
Gahrn-Hansen, B.4
Mordhorst, C.H.5
Norgaard-Pedersen, B.6
-
24
-
-
34548677546
-
Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics
-
Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166(12):1267-72.
-
(2007)
Eur J Pediatr
, vol.166
, Issue.12
, pp. 1267-1272
-
-
Rossi, G.A.1
Medici, M.C.2
Arcangeletti, M.C.3
Lanari, M.4
Merolla, R.5
Paparatti, U.D.6
-
25
-
-
0037387758
-
Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany
-
Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162(4):230-6.
-
(2003)
Eur J Pediatr
, vol.162
, Issue.4
, pp. 230-236
-
-
Liese, J.G.1
Grill, E.2
Fischer, B.3
Roeckl-Wiedmann, I.4
Carr, D.5
Belohradsky, B.H.6
-
26
-
-
3042760382
-
Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection
-
Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89(7):673-8.
-
(2004)
Arch Dis Child
, vol.89
, Issue.7
, pp. 673-678
-
-
Greenough, A.1
Alexander, J.2
Burgess, S.3
Bytham, J.4
Chetcuti, P.A.5
Hagan, J.6
-
27
-
-
16644380035
-
Economic analysis of palivizumab in infants with congenital heart disease
-
Yount LE, Mahle WT, Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114(6):1606-11.
-
(2004)
Pediatrics
, vol.114
, Issue.6
, pp. 1606-1611
-
-
Yount, L.E.1
Mahle, W.T.2
Yount, L.E.3
Mahle, W.T.4
-
28
-
-
33846066254
-
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis
-
Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. Pharmacoeconomics 2007;25(1):55-71.
-
(2007)
Pharmacoeconomics
, vol.25
, Issue.1
, pp. 55-71
-
-
Nuijten, M.J.C.1
Wittenberg, W.2
Lebmeier, M.3
|